quinolinic acid has been researched along with Shock, Septic in 1 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Shock, Septic: Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six patients with severe sepsis/septic shock and sepsis-associated immunosuppression (assessed using monocytic human leukocyte antigen-DR (mHLA-DR) expression) were assessed in a controlled trial of GM-CSF or placebo treatment for 8 days." | 6.75 | Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. ( Fotopoulou, C; Fusch, G; Hammoud, B; Hasper, D; Meisel, C; Pschowski, R; Reinke, P; Schefold, JC; Schütt, C; Volk, HD; Von Haehling, S; Zeden, JP, 2010) |
| "Thirty-six patients with severe sepsis/septic shock and sepsis-associated immunosuppression (assessed using monocytic human leukocyte antigen-DR (mHLA-DR) expression) were assessed in a controlled trial of GM-CSF or placebo treatment for 8 days." | 2.75 | Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. ( Fotopoulou, C; Fusch, G; Hammoud, B; Hasper, D; Meisel, C; Pschowski, R; Reinke, P; Schefold, JC; Schütt, C; Volk, HD; Von Haehling, S; Zeden, JP, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schefold, JC | 1 |
| Zeden, JP | 1 |
| Pschowski, R | 1 |
| Hammoud, B | 1 |
| Fotopoulou, C | 1 |
| Hasper, D | 1 |
| Fusch, G | 1 |
| Von Haehling, S | 1 |
| Volk, HD | 1 |
| Meisel, C | 1 |
| Schütt, C | 1 |
| Reinke, P | 1 |
1 trial available for quinolinic acid and Shock, Septic
| Article | Year |
|---|---|
Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.
Topics: Aged; Calcitonin; Calcitonin Gene-Related Peptide; Granulocyte-Macrophage Colony-Stimulating Factor; | 2010 |